Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report report published on Saturday. The firm issued a sell rating on the stock.

Separately, Roth Mkm restated a buy rating and issued a $20.00 price objective on shares of Bio-Path in a report on Monday, July 8th.

Bio-Path Stock Performance

BPTH stock opened at $0.87 on Friday. The firm’s 50-day moving average is $1.32 and its two-hundred day moving average is $2.38. Bio-Path has a 52 week low of $0.87 and a 52 week high of $21.60.

Bio-Path (NASDAQ:BPTH) last announced its earnings results on Thursday, August 15th. The company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.54) by $0.38. During the same period in the prior year, the firm posted ($10.60) EPS. Equities analysts anticipate that Bio-Path will post -6.2 earnings per share for the current fiscal year.

Institutional Trading of Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path as of its most recent filing with the Securities and Exchange Commission. 5.74% of the stock is owned by institutional investors and hedge funds.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.